Hyper Corporation Inc. (KOSDAQ:065650)

Market Cap	23.18B -82.9%
Revenue (ttm)	71.49B +30.2%
Net Income	-54.51B
EPS	-4,085.90
Shares Out	13.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,725
Average Volume	33,597
Open	1,830.00
Previous Close	1,822.00
Day's Range	1,695.00 - 1,830.00
52-Week Range	1,424.00 - 7,250.00
Beta	1.61
RSI	35.75
Earnings Date	Mar 20, 2026

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 1997
• Employees: 46
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065650

Financial Performance

In 2024, Hyper Corporation's revenue was 58.46 billion, an increase of 36.33% compared to the previous year's 42.88 billion. Losses were -80.36 billion, 3999.0% more than in 2023.